Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

CD24 as an innate immune checkpoint in solid tumors: biology, biomarker stratification, and therapeutic translation.

Frontiers in immunology·2026
Same author

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study.

BMC medicine·2026
Same author

Analysis of Efficacy and Survival Prognosis for Astragalus Polysaccharide Injection as Adjuvant Therapy in Non - Small Cell Lung Cancer: A Propensity Score Matching - Based Study.

Cancer management and research·2026
Same author

Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials.

The lancet. Gastroenterology & hepatology·2025
Same author

Analysis and Exploration of the Relationship Between the Status of Serum Tumor Markers and Clinicopathological Features and Curative Effects in Gastric Cancer and Gastroesophageal Junction Tumor.

OncoTargets and therapy·2025
Same author

Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

相关实验视频

Updated: May 26, 2025

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

16.5K

一线Sugemalimab加化学治疗晚期胃癌:GEMSTONE-303随机临床试验

Xiaotian Zhang1, Jufeng Wang2, Gang Wang3

  • 1State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China.

JAMA
|February 24, 2025
PubMed
概括

在晚期胃癌患者中,sugemalimab加化疗显著改善了整体存活率和无进展存活率. 在GEMSTONE-303试验中,这种组合治疗显示出可控的安全性.

更多相关视频

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

611
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

相关实验视频

Last Updated: May 26, 2025

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

16.5K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

611
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

科学领域:

  • 癌症学
  • 免疫疗法
  • 消化道癌症

背景情况:

  • 胃癌是全球癌症相关死亡的主要原因.
  • 在早期的胃癌研究中,sugemalimab是一种抗PD- L1抗体.
  • 在GEMSTONE-303试验中,研究了苏格马利马布与晚期胃癌的化疗联合治疗.

研究的目的:

  • 评估Sugemalib加 capecitabine和oxaliplatin (CAPOX) 与安慰剂加 CAPOX 的疗效.
  • 评估无法切除的,局部晚期或转移的胃/食道结腺癌的第一线治疗方法.
  • 专注于PD- L1综合阳性得分 (CPS) 为5或以上的患者.

主要方法:

  • 第三阶段,随机双盲,安慰剂对照试验 (GEMSTONE-303).
  • 479名患者患有局部晚期/ 转移性胃腺癌或GEJ,PD- L1 CPS ≥5.
  • 治疗组: 苏格马利马布 (1200 mg IV q3w) + 卡波克斯与安慰剂+卡波克斯.

主要成果:

  • 苏格玛利马布显著改善了整体存活率 (中位数为15. 6个月;HR为0. 75;P=. 006).
  • 无进展的存活期也显著改善 (中位数为7. 6个月;HR为0. 66;P<. 001).
  • 与治疗相关的≥3级不良事件相似 (53. 9%与50. 6%).

结论:

  • 在以前未接受过治疗的晚期胃癌患者中,Sugemalimab加CAPOX具有显著的生存益处.
  • 这种组合显示出可管理的安全性.
  • 这种治疗方案代表了PD-L1阳性胃癌的潜在新标准治疗.